SEC Form 4 · accession 0001209191-15-078403
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yuchun Lee
Director
Period of report
Nov 2, 2015
Accepted (ET)
Nov 4, 2015 · 4:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 2, 2015 | M | 1,334 | $57.27 | A | 1,750 | D | |
| Common Stock | Nov 2, 2015 | S | 100 | $123.64 | D | 1,650 | D | |
| Common StockF2,F3 | Nov 2, 2015 | S | 525 | $125.93 | D | 1,125 | D | |
| Common StockF2,F4 | Nov 2, 2015 | S | 500 | $126.98 | D | 625 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F5 | $57.27 | Nov 2, 2015 | M | 1,334 | D | — | Sep 13, 2022 | Common Stock | 1,334 | 26,000 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- F2Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $125.93 (range $125.38 to $126.19).
- F4Open market sales reported on this line occurred at a weighted average price of $126.98 (range $126.64 to $127.57).
- F5The option vests in 16 quarterly installments from 09/14/2012.